ArticleBiochemistry and biophysics reports2025
Exploring LAT-derived miRNAs as regulatory agents of EphrinA3 in glioblastoma multiforme.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study focuses on the findings related to Latency- Associated Transcript (LAT)- derived miRNAs and their interactions with ephrin family genes, especially Method: The differential expression of the Ephrin (EFN) family in GBM was analyzed using TCGA and GEO databases, alongside survival data from the Kaplan-Meier Plotter. Bioinformatics predicted LAT-derived miRNAs targeting EFN genes, which were validated in vitro. Luciferase assays confirmed miR-H2 and miR-H3's targeting of Results: EphrinA3 is significantly overexpressed in GBM tissues, and its expression level is correlated with the prognosis of GBM patients. Both miR-H2-3p and miR-H3-3p effectively target EphrinA3, resulting in approximately a twofold reduction in luciferase activity when assessed individually. Notably, this suppressive effect is enhanced fourfold in cells expressing LAT transcript. Furthermore, both miRNAs significantly downregulate Conclusion: The study highlights the potential of targeting EphrinA3 through HSV-1-derived miRNAs, particularly miR-H2 and miR-H3, as a promising therapeutic strategy. These findings suggest that modulating EphrinA3 expression could enhance treatment efficacy while minimizing off-target effects, paving the way for innovative approaches to combat GBM. Further research is warranted to explore the clinical implications of these insights in developing effective therapies for this aggressive cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.